News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News LINC 2020 Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment L.A. McKeown January 31, 2020
News Conference News ISET 2020 FDA’s First Take on New Paclitaxel Concerns in CLI Caitlin E. Cox January 24, 2020
News Conference News SCAI 2019 Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics Yael L. Maxwell May 21, 2019
News Conference News CRT 2019 SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients Yael L. Maxwell March 14, 2019
News Conference News CRT 2019 Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy L.A. McKeown March 06, 2019
News Conference News VIVA 2018 No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy L.A. McKeown November 13, 2018
News Conference News ISET 2018 Next-Generation Large-Bore Closure Devices Arrive Caitlin E. Cox February 05, 2018
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News VIVA 2017 Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients L.A. McKeown September 11, 2017
News Conference News TCT 2016 ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions L.A. McKeown November 07, 2016
News Conference News VIVA 2016 Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions L.A. McKeown September 22, 2016